Kyverna Therapeutics reports positive one-year miv-cel data in SPS; rolling BLA on track for Q4

Kyverna Therapeutics reported positive one-year durability and safety data for miv-cel in stiff person syndrome and longer-term Phase 2 follow-up in generalized myasthenia gravis.Key Highlights:Original SEC Filing: Kyverna Therapeutics, Inc. [ KYTX ] - 8-K - Sep. 24, 2026This is an AI-powered summa…